DanCann Pharma A/S (NGM:DANCAN)

Market Cap	792.75K
Revenue (ttm)	5.94M
Net Income (ttm)	-14.78M
Shares Out	3.99M
EPS (ttm)	-2.54
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	545,270
Average Volume	155,238
Open	0.1420
Previous Close	0.1440
Day's Range	0.1120 - 0.1550
52-Week Range	0.1120 - 2.2000
Beta	1.91
RSI	30.77
Earnings Date	Feb 27, 2026

About DanCann Pharma

DanCann Pharma A/S, a biopharmaceutical company, focuses on commercializing new therapeutic cannabinoids in various disease areas. The company distributes prescription cannabinoid-based medicines. It develops EXT03 CannGros, an oral extract based on Bediol; EXT04 CannGros, an oral extract based on Bedrolite; EXT02 CannGros, an oral extract based on Bedrocan; FLS04 CannGros granulate; FLS05 CannGros flos; and OTC01 CannGros, OTC02 CannGros, and OTC03 CannGros extracts. The company was incorporated in 2018 and is based in Ansager, Denmark.

• Industry: Pharmaceutical Preparations
• Founded: 2018
• Employees: 5
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: DANCAN

Financial Performance

In 2024, DanCann Pharma's revenue was 7.37 million, an increase of 3.06% compared to the previous year's 7.15 million. Losses were -8.35 million, -86.59% less than in 2023.

Financial numbers in DKK